Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2^+/- Mice Is Superior to Everolimus Alone.

However, the solid tumor count was low in the combination therapy group, and it is unsurprising that although their results were comparable to those of the sorafenib only group, they did not reach statistical significance.

also in 111,027 other papers